Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb - Research Grade |
---|---|
Source | CAS 476181-74-5 |
Species | Homo sapiens |
Expression system | Mammalian cells |
Molecular weight | 147kDa |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Golimumab,CNTO 148,TNFA, TNF alpha,anti-TNFA, TNF alpha |
Reference | PX-TA1129 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Golimumab is a human IgG1 alpha monoclonal antibody, developped from genetically engineered mice immunized with human TNFalpha. Golimumab binds to and inhibits soluble and transmembrane human TNFalpha. Elevated TNFalpha is related to chronic inflammation. Therefore, golimumab can be used in adults,for the treatment of active rheumatoid arthritis (RA), active psoriatic arthritis ( PsA), active ankylosing spondylitis (AS), ulcerative colitis (UC). In the United States and Canada, golimumab is sold under the Simponi® brand. The FDA label includes a black box that warns of serious infections and malignant tumors.
Immobilized Human TNFa Recombinant Protein (cat. No. PX-P3058) at 0.5µg/mL (100µL/well) can bind Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb (cat. No. PX-TA1129) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 3.028M.
Golimumab Biosimilar - Anti-TNFA, TNF alpha mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.